PharmAthene, Inc. PIP announced today that new non-clinical animal data from the Company's
SparVax^® next-generation anthrax vaccine program were presented at the 53^rd
Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC) in Denver, Co. The data presented showed that immunization with
SparVax^® provides dose-dependent protection against lethal anthrax infection.
Dr. Sherry Crowe, Director, Immunology at PharmAthene, discussed the results
in an oral presentation entitled, "Recombinant Protective Antigen Vaccine
(SparVax^®) Provides Protection against Lethal Challenge with Bacillus
anthracis in New Zealand White Rabbits."
Summary of SparVax^® Findings Reported
The need for newer anthrax vaccines based on modern vaccine technology, which
offer the potential for improved safety, convenience and cost-effectiveness,
is widely acknowledged. SparVax^® is a next-generation anthrax vaccine based
on recombinant protective antigen (rPA), the principal virulence factor of the
organism, B. anthracis. It is being developed for pre- and post-exposure
protection against anthrax.
Previous non-clinical animal studies have demonstrated that immunization with
SparVax^® stimulates the production of anti-PA antibodies that provide
protection against anthrax infection. The objective of the current study was
to provide further confirmation of the immunogenicity and efficacy of
SparVax^® (manufactured in the U.S.) and determine the optimal dose range for
protection.
In the current study, New Zealand White rabbits were administered escalating
doses of SparVax^® ranging from 0.003 micrograms to 1.0 micrograms of rPA.
Control animals received either no immunization or were administered saline.
Following immunization, the animals were challenged with B. anthracis spores
(Ames strain).
The results demonstrated that SparVax^® was effective in providing protection
against lethal inhalation anthrax challenge and resulted in no adverse
clinical observations. In the study, immunization with SparVax^® stimulated a
dose-dependent antibody response, which correlated with survival.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in